Key Highlights
● Creative Medical Technology Holdings bought 4,000,000 BioDefense, Inc. shares from Creative Acquisition Corp effective September 24, 2026, paying $200,000 in cash plus 1,000,000 CELZ shares.
● The purchase raised Creative Medical's BioDefense ownership to 16,000,000 shares, or 80%, while Creative Acquisition Corp retains the remaining 4,000,000 shares, or 20%.
● CEO Timothy Warbington sits on both sides of the deal, serving as President and CEO of Creative Medical while also serving as Chairman and CEO of Creative Acquisition Corp and indirectly owning all of its shares.
● The filing does not describe any special committee, independent valuation, or board approval process used to set the transaction's price.
Creative Medical Technology Holdings (NASDAQ:CELZ) disclosed in an 8-K filed September 25, 2026 that it bought 4,000,000 shares of BioDefense, Inc. from Creative Acquisition Corp, a company controlled by Creative Medical's own chief executive, paying $200,000 in cash plus 1,000,000 shares of Creative Medical stock and lifting its BioDefense ownership to 80%.
The Deal's Structure
According to a Stock Purchase Agreement filed as Exhibit 10.1, Creative Medical acquired the BioDefense shares from Creative Acquisition Corp effective September 24, 2026. The consideration was split between cash, "$200,000.00," and equity, "1,000,000 shares of the common stock of the Purchaser." After the transaction, Creative Medical holds 16,000,000 BioDefense shares, an 80% stake, while Creative Acquisition Corp retains the remaining 4,000,000 shares, or 20%.
The agreement's representations are standard for a private stock sale: the seller warrants it holds clear title to the shares free of encumbrances, both companies confirm they have authority to sign and that the deal does not violate any law binding on them, and the BioDefense shares being sold are unregistered and must be held indefinitely absent registration or an available exemption, with restrictive legends placed on the certificates. The seller likewise acknowledges taking the CELZ shares strictly as an investment, aware that they too are unregistered. The stock power delivering the BioDefense shares is attached as Exhibit A, and the agreement is governed by Nevada law with representations surviving closing.
The Related-Party Wrinkle
The 8-K is explicit that this is a related-party transaction: Timothy Warbington, who serves as President and Chief Executive Officer of Creative Medical, is "also the Chairman and Chief Executive Officer of CAC and indirectly owns all of its outstanding shares." That means Warbington sat on both sides of the negotiation, as the buyer's top executive and, through his ownership of Creative Acquisition Corp, effectively as the seller as well.
Companies are required to flag such related-party dealings because the usual arm's-length assumption behind ordinary commercial negotiations does not fully apply when the same person controls both counterparties. The filing does not describe any special committee, independent valuation, or board approval process used to set the $200,000-cash-plus-1,000,000-share price, so investors do not have disclosed detail on how that consideration was negotiated or benchmarked.
Items Disclosed and What BioDefense Is
The 8-K covers three items: 1.01 (entry into a material definitive agreement), 3.02 (unregistered sales of Equity securities, referring to the CELZ shares issued to Creative Acquisition Corp as part of the consideration), and 9.01 (financial statements and exhibits). The filing identifies BioDefense, Inc. only as the company whose shares changed hands; it does not include a fresh description of BioDefense's Business operations within this particular 8-K.
Item 3.02 disclosures exist specifically to flag when a company issues securities without registering them under the Securities Act, typically relying on an exemption available for private transactions rather than public offerings. Pairing that disclosure with the Item 1.01 material-agreement disclosure gives investors both halves of the picture: what was agreed to, and how the new CELZ shares handed to Creative Acquisition Corp were legally issued.
Disclosures Investors Should Track Next
Because the shares issued to Creative Acquisition Corp were unregistered, watch for any future registration statement or resale filing covering those 1,000,000 CELZ shares. Investors should also watch Creative Medical's subsequent periodic reports for how it accounts for and describes its now-80% ownership of BioDefense, since a control stake of that size typically brings BioDefense's results onto Creative Medical's own financial statements. The 8-K sets no further deadlines or conditions beyond the closing, which the agreement states occurred simultaneously with signing on September 24, 2026. Investors may also watch for whether Creative Medical or BioDefense discloses any independent valuation work behind the transaction price in a future filing, given the related-party nature of the sale.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...